Amicus Therapeutics develops and commercializes orphan drug products for rare diseases, particularly neuromuscular disorders, utilizing a pipeline of gene therapy candidates.
Investors may view Amicus as an attractive opportunity given its promising pipeline of gene therapies for rare diseases with high unmet medical need. The recent revenue growth and improving operational cash flow suggest the company is successfully transitioning towards commercial viability. Strategic partnerships and a strong regulatory track record could unlock significant value if key clinical trials succeed.
The stock carries substantial risk due to its persistent net losses, large retained earnings deficit of -$2.77B, and heavy reliance on external financing. High competition in the gene therapy space and potential reimbursement challenges could limit market penetration for its products. Without achieving profitability soon, the company may struggle to sustain operations without further dilution or debt restructuring.
Amicus Therapeutics (FOLD) is a biopharmaceutical company specializing in developing orphan drugs for rare diseases, primarily focusing on gene therapies for neuromuscular disorders. The company serves patients in the United States and international markets with its proprietary treatments addressing severe genetic conditions. Key products include gene transfer therapies designed to provide long-term management of life-threatening rare diseases.
In 2025, Amicus Therapeutics reported revenue of $634.2M, representing a 20% increase from the previous year's $528.3M, indicating strong commercial momentum for its approved therapies. However, net income remained negative at -$27.1M, reflecting continued high R&D and operational expenses despite improving cash flow from operations of $33.1M. The company's ability to manage its substantial debt load while funding ongoing clinical trials will be critical as it seeks to achieve profitability in future years.
The rare disease industry is characterized by small patient populations but high-value treatments, often supported by government incentives like orphan drug designations. Gene therapy represents a transformative approach in this sector, offering potential cures rather than just symptom management. Regulatory pathways are evolving to accommodate the unique characteristics of these innovative therapies while ensuring patient safety and access.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $329.2M | $399.4M | $528.3M | $634.2M |
| Cost of Revenue | $38.6M | $37.3M | $52.9M | $72.9M |
| Gross Profit | $290.6M | $362.0M | $475.4M | $561.3M |
| Operating Expenses | $502.8M | $439.2M | $450.5M | $528.5M |
| Operating Income | $-212.1M | $-77.2M | $24.9M | $32.8M |
| G&A | $213.0M | $275.3M | $323.4M | $383.5M |
| Stock-Based Comp | $76.5M | $86.1M | $84.9M | $87.4M |
| D&A | $5.3M | $7.9M | $8.5M | $7.5M |
| Depreciation | $4.8M | $4.8M | $5.0M | $3.9M |
| Amortization | — | $2.5M | $3.3M | $3.3M |
| Other OpEx | $289.7M | $164.0M | $127.1M | $145.0M |
| Non-Operating Income | $-29.9M | $-72.9M | $-53.6M | $-32.6M |
| Interest Expense | $37.1M | $50.1M | — | — |
| Interest Income | $3.0M | $7.1M | $5.4M | $3.3M |
| Pre-Tax Income | $-242.0M | $-150.1M | $-28.8M | $191.0K |
| Income Tax | $-5.5M | $1.5M | $27.4M | $27.3M |
| Continuing Ops | $-236.6M | $-151.6M | $-56.1M | $-27.1M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-236.6M | $-151.6M | $-56.1M | $-27.1M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-236.6M | $-151.6M | $-56.1M | $-27.1M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $423.8M | $483.1M | $504.7M | $676.2M |
| Cash & Equivalents | $148.8M | $247.0M | $213.8M | $214.0M |
| Marketable Securities | $144.8M | $39.2M | $36.2M | $79.5M |
| Accounts Receivable | $66.2M | $87.6M | $101.1M | $115.3M |
| Inventory | $23.8M | $59.7M | $118.8M | $228.8M |
| Prepaid Expenses | $40.2M | $49.5M | $34.9M | $38.5M |
| Other Current Assets | $0 | $0 | $0 | $0 |
| Long-Term Assets | $300.4M | $294.8M | $280.3M | $273.7M |
| PP&E (Net) | $30.8M | $31.7M | $29.4M | $27.1M |
| Intangibles | $23.0M | $20.5M | $17.2M | $13.9M |
| Goodwill | $197.8M | $197.8M | $197.8M | $197.8M |
| Operating Leases | $29.5M | $26.3M | $22.3M | $21.1M |
| Other LT Assets | $19.2M | $18.6M | $13.6M | $13.7M |
| Total Assets | $724.2M | $777.9M | $785.0M | $949.9M |
| Current Liabilities | $139.0M | $167.7M | $148.7M | $237.8M |
| Accounts Payable | $15.4M | $15.1M | $12.9M | $28.6M |
| Current Leases | $8.6M | $8.3M | $8.5M | $8.7M |
| Other Current Liab | $115.1M | $144.2M | $127.3M | $200.5M |
| Long-Term Liabilities | $462.1M | $450.0M | $442.3M | $437.8M |
| LT Operating Leases | $51.6M | $48.9M | $45.1M | $41.0M |
| Other LT Liab | $410.5M | $401.1M | $397.2M | $396.8M |
| Total Liabilities | $601.1M | $617.7M | $591.0M | $675.6M |
| Shareholders' Equity | $123.0M | $160.2M | $194.0M | $274.2M |
| Retained Earnings | $-2.53B | $-2.68B | $-2.74B | $-2.77B |
| Total L&E | $724.2M | $777.9M | $785.0M | $949.9M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-236.6M | $-151.6M | $-56.1M | $-27.1M |
| Non-Cash Adjustments | $47.5M | $-39.5M | $-40.4M | $-141.2M |
| Working Capital Changes | $22.5M | $122.0M | $62.7M | $201.5M |
| Cash from Operations | $-166.6M | $-69.1M | $-33.9M | $33.1M |
| Capital Expenditures | $3.8M | $7.4M | $3.6M | $3.3M |
| Cash from Investing | $92.3M | $98.1M | $-560.0K | $-46.4M |
| Debt Repayments | $0 | $408.0M | $0 | $0 |
| Cash from Financing | $-7.5M | $61.7M | $5.1M | $610.0K |
| FX Effect | $-14.6M | $6.3M | $-4.0M | $13.3M |
| Net Change in Cash | $-96.3M | $97.0M | $-33.4M | $600.0K |
| Beginning Cash | $249.5M | $153.1M | $250.1M | $216.7M |
| Ending Cash | $153.1M | $250.1M | $216.7M | $217.3M |
The company's revenue is driven by its commercialization of approved gene transfer therapies, with significant contributions from ongoing clinical development programs. Major revenue streams include sales of existing approved products like Elevidys and revenues generated from strategic collaborations with partners in the rare disease space. The business model relies heavily on high-margin gene therapy sales supported by substantial R&D investments and regulatory milestones.
The company faces significant commercialization risks as it transitions from clinical trials to market, requiring substantial upfront investments with uncertain future revenue returns. Regulatory approval processes for gene therapies are lengthy and costly, and any delays could impact cash flow and valuation significantly. High levels of debt and a large retained earnings deficit create financial pressure, limiting flexibility for further capital expenditures or acquisitions. Market acceptance of novel gene therapies remains unproven at scale, posing potential challenges to achieving projected sales targets.
Amicus possesses a robust pipeline of proprietary gene transfer therapies targeting unmet medical needs in the rare disease market. The company has established strong partnerships with major healthcare providers and payers to facilitate patient access and reimbursement for its high-value treatments. Its deep expertise in neuromuscular disorders and successful track record in advancing clinical candidates provide a distinct advantage in securing regulatory approvals.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.